I suspect leading up to or after the launch of Market or

New Post Public Reply Private Reply Replies (0) Message Board
redspeed
897
I suspect leading up to or after the launch of Market or shortly after, the sp will go up because of the interest from institutions. I suspect it will double, if not triple once people see the big brands and start calculating the revenue it will generate. My speculation is supported by facts which I'll get to a minute.

Eventually you'll see whatnot valuation, but not today, even though some are running around saying Verb is $4B-$6B right now and out of their minds. That stupid pumping hurts all of our investment and just eggs on bashers.

First you'll see Bambuser valuation, in my opinion which is $310M once Market is launched and gets revenue rolling in. It's the closest public company I can find as a comp. Actually Verb's market cap should be higher this year, post Market launch since Bambuser doesn't have anything like Market that I am aware. They do it for individual companies like Verb does today.

Bambuser's revenue last quarter was $5.4M, but it's MRR (monthly reoccurring revenue) was only $660K, which is about $8M a year. Verb's revenue YTD MRR was ~$5M and they are expecting to add another $1M so not too far off from Bambuser.

Previous quarter Bambuser's revenue was $3.8M so they are adding about $1.5M a quarter. Their MRR was $507K in Q2 so increasing their MRR about $150K a quarter. $507K MMR is about $6M a year.

See where I am going with this?

Verb's MRR should be $500K shortly. Same as what Bambuser was in Q2 so Verb MRR is lagging Bambuser about 6 months which is fine.

What is funny is the OMG view stock bashers portray when companies are adding MMR at $100K at a time pretending companies should be adding millions monthly but it doesn't work like that for small companies.

What you may not realize is Market won't necessarily add to much to MRR since the bulk of the revenue will be from a percent of sales but it's great then have other products that will continue to add to MRR. I suspect there will be some MRR from people wanting certain things though but I don't think it would be a lot.

Verb's total revenue was about $7.8M YTD. Let's pretend it's more or less $10M to use a round number for 2021. Bambuser's is about $11.5M YTD. So let's say 2021 would be about $18.5M?

So a bit higher than Verb's but the point is, Verb doesn't even have to add a lot of revenue from Market to rocket up the share price. Verb's other products will continue to grow. Let's pick a number and say the other ones grows 40% this year. So from $10M to $14M.

What would it take for Market to add $4M of revenue? I'm guessing about $40M of sales but I don't think year 1 of Market matters to much. It's really what is the rate of growth. Starting at $0, the growth rate will be pretty high.

So in my opinion, that's what it would take to get to a $310M market cap. Keep in mind Bambuser's valuation, like a lot of tech stocks, took quite a haircut. For them 50% chop, but still a nice valuation.

If Bambuser gets back up to $600M cap like last year, does that mean Verb will too with a little more revenue? Possibly...

Bambusers market cap today is about 3.4 times higher than Verbs. When Verb gets to where Bambuser is, that is a $4+ stock. If they get to where Bambuser was, that is a $8 stock. Once the Market train starts rolling, I don't see growth slowing down, only accelerating. Some of these private video selling sites are raking in some nice estimated revenue.

Something else to think about. If Verb's sp moves to $4-$8 this year, what would a buyout share price look like? Certainly it wouldn't be $4 or $8 in my opinion.

Now you know why the initial conversion price of $3.00 was agreeable.








TON Strategy Co. (TONX) Stock Research Links

TONX Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 501

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading
FASTEN Data Offers an Early Look at Ladera Closure

Updated Category News Views 130

Femoral access may be the unglamorous part of a valve procedure, but it is where an otherwise tidy case can turn ugly in a hurry. That makes Ladera Medical's full FASTEN data worth a careful look. The company reported results in 55 patients undergoing transfemoral TAVR/TAVI, and the numbers presented at London Valves 2026 suggest its large-bore closure system may address...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 564

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 707

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
NatGasHub’s 391% Growth Signals a Real Pipeline Shift

Updated Category News Views 445

Three hundred-plus pipelines is a lot of messy plumbing to tame, and NatGasHub has apparently found a lucrative way to do it. The Houston software company landed at No. 182 on Deloitte’s 2026 Technology Fast 500 after reporting 391% revenue growth from 2022 through 2025. That is a serious number, even in a ranking built to showcase companies sprinting uphill. More...

Continue Reading
Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 270

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading
UAE Ties Diplomacy, Media and AI Into a Shared Signal

Updated Category News Views 128

Influence is getting harder to measure, and easier to squander, which is why the message from Ajman deserves more than a polite nod. At the 2026 Ajman Media Forum, THE SIGNAL, Foreign Affairs Undersecretary Omar Obaid Alhesan Alshamsi made the UAE’s position plain: diplomacy and media are no longer separate lanes. Both operate on words, context, trust and the difficult...

Continue Reading
Sitting, Lymph Flow, and a Supplement Maker's Pitch

Updated Category News Views 299

By late afternoon, a chair can feel like it has quietly won the argument against your legs. PureHealth Research is leaning into that familiar heavy, puffy-legged feeling with a reminder about lymphatic flow—and, naturally, an eight-ingredient supplement positioned alongside it. The broad message is sensible. The sales layer needs the usual healthy squint. Movement Does...

Continue Reading
CARsgen's CT1182 Data Opens a Careful New CAR-T Test

Updated Category News Views 112

Six very sick lymphoma patients are not a victory lap, but they can still make the whole cell-therapy field sit up straighter. CARsgen has disclosed first clinical results for CT1182, an in vivo CAR-T candidate built on its CARvivo platform, and the early package is plainly more interesting than the usual preclinical chest-thumping. The company reported three complete...

Continue Reading
D-Wave Investors Face a December 15 Lead Plaintiff Clock

Updated Category News Views 496

August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...

Continue Reading